<DOC>
	<DOCNO>NCT02537977</DOCNO>
	<brief_summary>Relapsed/refractory leukemia lymphoma lack effective treatment . The cancer immunotherapy chimeric antigen receptor ( CAR ) T cell provide potent new approach . In clinical trial , investigator aim assess safety efficacy administer T cell express anti-CD19 CARs patient chemotherapy resistant refractory CD19 positive B cell malignancy include leukemia lymphoma .</brief_summary>
	<brief_title>CD19-directed CAR T Cells Therapy Relapsed/Refractory B Cell Malignancy</brief_title>
	<detailed_description>Tongji Hospital Tongji University develop investigational approach treat patient CD19 positive B cell malignancy involve take white blood cell patient , grow laboratory large number , genetically modify specific cell lentivirus attack CD19 positive cell , give cell back patients.The main purpose study assess safety efficacy treatment anti-CD19 CAR-T cell patient chemotherapy resistant refractory CD19 positive B cell malignancy include leukemia lymphoma .</detailed_description>
	<criteria>Patients CD19+ leukemia lymphoma , meet follow criterion : At least 2 prior combination chemotherapy regimen ( include single agent monoclonal antibody ( Rituximab ) therapy ) Less 1 year last chemotherapy progression Not eligible appropriate alloHSCT To age 12 70 year Estimated survival ≥ 6 month , ≤ 2 year ECOG score ≤2 Relapse autoHSCT Women childbearing potential must urine pregnancy test take proven negative prior treatment . All patient agree use reliable method contraception trial period followup last time Voluntary participation clinical trial sign inform consent History epilepsy CNS disease Patients GVHD , need treatment immunosuppressive agent Patients prolong QT interval severe heart disease Patients pregnancy breastfeed period Uncontrolled active infection Active hepatitis B hepatitis C infection Concurrent use systemic steroid . Recent current use inhale steroid exclusionary Previously treatment gene therapy product Feasibility assessment screen demonstrates &lt; 20 % transduction target lymphocytes , insufficient expansion ( &lt; 5fold ) response CD3/CD28 costimulation ALT /AST &gt; 3 x normal value ; Creatinine &gt; 2.5 mg/dl ; Bilirubin &gt; 2.0 mg/dl Any uncontrolled medical disorder researcher consider eligible participate clinical trial HIV infection Any situation would increase dangerousness subject disturb outcome clinical study accord researcher 's evaluation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>